{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T12:16:36Z","timestamp":1769948196478,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.ajo.2009.06.003","type":"journal-article","created":{"date-parts":[[2009,8,7]],"date-time":"2009-08-07T04:31:40Z","timestamp":1249619500000},"page":"696-703.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["High-dose Daclizumab for the Treatment of Juvenile Idiopathic Arthritis\u2013Associated Active Anterior Uveitis"],"prefix":"10.1016","volume":"148","author":[{"given":"H. Nida","family":"Sen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Levy-Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa J.","family":"Faia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karyl S.","family":"Barron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keri","family":"Hammel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert B.","family":"Nussenblatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2009.06.003_bib1","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ajo.2009.06.003_bib2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/art.20945","article-title":"Patients with anti-nuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease","volume":"52","author":"Ravelli","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajo.2009.06.003_bib3","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0161-6420(01)00773-4","article-title":"Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study","volume":"108","author":"Kotaniemi","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2009.06.003_bib4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/00055735-200312000-00013","article-title":"Diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis","volume":"14","author":"Foster","year":"2003","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ajo.2009.06.003_bib5","first-page":"2031","article-title":"Prevalence and outcome of uveitis in a regional cohort of patients with juvenile rheumatoid arthritis","volume":"24","author":"Chalom","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ajo.2009.06.003_bib6","first-page":"2446","article-title":"Early predictors of severe course of uveitis in oligoarticular juvenile idiopathic arthritis","volume":"29","author":"Zulian","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ajo.2009.06.003_bib7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0002-9394(03)00225-3","article-title":"Factors related to severe uveitis at diagnosis in children with juvenile idiopathic arthritis in a screening program","volume":"135","author":"Chia","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.06.003_bib8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ajo.2006.11.025","article-title":"Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis","volume":"143","author":"Woreta","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.06.003_bib9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0161-6420(97)30329-7","article-title":"Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis","volume":"104","author":"Dana","year":"1997","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2009.06.003_bib10","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/S0161-6420(87)80007-6","article-title":"Prognostic factors in the uveitis of juvenile rheumatoid arthritis","volume":"94","author":"Wolf","year":"1987","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2009.06.003_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/bjo.86.1.51","article-title":"An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood","volume":"86","author":"Edelsten","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.06.003_bib12","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/art.1780290615","article-title":"The relationship between ocular and articular disease activity in children with juvenile rheumatoid arthritis and associated uveitis","volume":"29","author":"Rosenberg","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajo.2009.06.003_bib13","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0008-4182(04)80026-7","article-title":"Juvenile arthritis-associated uveitis: visual outcomes and prognosis","volume":"39","author":"Chen","year":"2004","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.06.003_bib14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0002-9394(75)90529-2","article-title":"Iridocyclitis associated with juvenile rheumatoid arthritis","volume":"80","author":"Key","year":"1975","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.06.003_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/09273940590909220","article-title":"Visual outcomes of juvenile rheumatoid arthritis-associated uveitis in adults","volume":"13","author":"\u00d6zdal","year":"2005","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ajo.2009.06.003_bib16","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ajo.2007.01.033","article-title":"Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss","volume":"143","author":"Thorne","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.06.003_bib17","first-page":"S217","article-title":"The ocular manifestations of juvenile rheumatoid arthritis","volume":"20","author":"Chylack","year":"1977","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajo.2009.06.003_bib18","first-page":"362","article-title":"Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis","volume":"32","author":"Foeldvari","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ajo.2009.06.003_bib19","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/bjo.82.7.737","article-title":"Cyclosporin A therapy in refractory noninfectious childhood uveitis","volume":"82","author":"Kilmartin","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.06.003_bib20","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/ard.2006.058248","article-title":"Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis","volume":"66","author":"Tynj\u00e4l\u00e4","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajo.2009.06.003_bib21","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/kel030","article-title":"Tumour necrosis factor a inhibitors in the treatment of childhood uveitis","volume":"45","author":"Saurenmann","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ajo.2009.06.003_bib22","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2005.09.037","article-title":"Retrospective case review of pediatric patients with uveitis treated with infliximab","volume":"113","author":"Rajaraman","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2009.06.003_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","article-title":"A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"53","author":"Smith","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajo.2009.06.003_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199801153380304","article-title":"Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation","volume":"338","author":"Vincenti","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2009.06.003_bib25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00007890-200109150-00017","article-title":"Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation","volume":"72","author":"Bumgardner","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.ajo.2009.06.003_bib26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaut.2008.05.001","article-title":"High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis","volume":"31","author":"Yeh","year":"2008","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ajo.2009.06.003_bib27","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/bjo.2007.124081","article-title":"Biological response modifier therapy for refractory childhood uveitis","volume":"91","author":"Gallagher","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.06.003_bib28","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ophtha.2004.12.034","article-title":"Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series","volume":"112","author":"Nussenblatt","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2009.06.003_bib29","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1073\/pnas.96.13.7462","article-title":"Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I\/II clinical trial","volume":"96","author":"Nussenblatt","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajo.2009.06.003_bib30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0896-8411(03)00113-6","article-title":"Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration","volume":"21","author":"Nussenblatt","year":"2003","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ajo.2009.06.003_bib31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.06.003_bib32","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/kel030","article-title":"Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis","volume":"45","author":"Saurenmann","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ajo.2009.06.003_bib33","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ophtha.2006.01.005","article-title":"Favorable response to high-dose infliximab for refractory childhood uveitis","volume":"113","author":"Kahn","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2009.06.003_bib34","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ophtha.2004.12.036","article-title":"Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy","volume":"112","author":"Kiss","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2009.06.003_bib35","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0161-6420(02)01932-2","article-title":"Treatment of ocular inflammatory disorders with daclizumab","volume":"110","author":"Papaliodis","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2009.06.003_bib36","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.4049\/jimmunol.174.9.5187","article-title":"Cutting edge: In vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis","volume":"174","author":"Li","year":"2005","journal-title":"J Immunol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939409004036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939409004036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:00:16Z","timestamp":1757595616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939409004036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0002939409004036"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2009.06.003","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose Daclizumab for the Treatment of Juvenile Idiopathic Arthritis\u2013Associated Active Anterior Uveitis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2009.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}